论文部分内容阅读
目的:观察扶正抗癌方加减联合化疗方案治疗中晚期食管癌临床疗效。方法:将79例中晚期食管癌患者根据其意愿分为联合组(n=55)和对照组(n=24),对照组予以DDP加NVB化疗方案治疗,联合组则在对照组基础上联合使用扶正抗癌方。观察2组患者临床疗效及不良反应发生情况,记录其症状评分差异。结果:联合组总有效率为61.8%,高于对照组的37.5%,差异有统计学意义(P<0.05)。治疗后,联合组纳差、疼痛及吞咽梗阻评分低于对照组,差异均有统计学意义(P<0.05)。2组毒副反应发生情况比较,差异有统计学意义(P<0.05)。结论:对中晚期食管癌患者予以扶正抗癌方联合化疗方案治疗,疗效确切,值得推广应用。
Objective: To observe the clinical effects of Fuzheng Kangai Fang plus combined with chemotherapy in the treatment of advanced esophageal cancer. Methods: According to their wishes, 79 patients with advanced esophageal cancer were divided into the combined group (n = 55) and the control group (n = 24). The control group received DDP plus NVB chemotherapy. The combined group was combined with the control group Fuzheng anti-cancer side. The clinical efficacy and adverse reactions of two groups were observed, and the difference of symptom score was recorded. Results: The total effective rate in the combined group was 61.8%, which was higher than that in the control group (37.5%), the difference was statistically significant (P <0.05). After treatment, the score of joint anorexia, pain and swallowing obstruction was lower than that of the control group, the differences were statistically significant (P <0.05). There were significant differences between the two groups in the incidence of side effects (P <0.05). Conclusion: The treatment of advanced esophageal cancer patients with Fuzheng anti-cancer combined with chemotherapy regimen, the exact effect, it is worth promoting the application.